Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12P AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/047575MODIFIED CORONAVIRUS STRUCTURAL PROTEIN
WO 10.03.2022
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CA2021/051201 Applicant MEDICAGO INC. Inventor LAVOIE, Pierre-Olivier
Modified coronaviras spike (S)-protein, virus-like particle (VLPs) comprising the modified S protein and nucleic acids encoding modified S protein are provided. Methods for modified S-protein and VLP production in a host or host cell are also described. The modified S-protein may comprise a transmembrane domain (TM) or portion of a TM, and a cytosolic tail (CT) or of a CT, wherein the CT or portion of the CT is derived from an influenza hemagglutinin (HA) protein and wherein the TM or portion of the TM is heterologous to the CT or portion of the CT. In addition a method for inducing immunity to a coronaviras infection in a subject, comprising administering a composition comprising the modified coronaviras (S)-protein or VLP to the subject is described.
2.WO/2022/060900SHARK-DERIVED BINDING MOLECULES FOR SARS-COV-2 CORONAVIRUS AND USES THEREOF
WO 24.03.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2021/050545 Applicant THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. Inventor JOYCE, Michael Gordon
Disclosed herein are shark-derived antibodies and binding molecules with high binding affinity for SARS-CoV-2 coronavirus and the use thereof. Some of the shark-derived antibodies and binding molecules also demonstrate cross-reactivity with and neutralization of other related sarbecoviruses. The complementarity determining region (CDR) sequences and binding characteristics for these antibodies and binding molecules are provided. Also disclosed are the use of these antibodies and binding molecules to detect SARS-CoV-2 coronavirus or other related sarbecoviruses or to prevent or treat SARS-CoV-2 coronavirus or other related sarbecovirus infections.
3.WO/2022/125523MANUFACTURE OF GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR
WO 16.06.2022
Int.Class C12N 5/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
Appl.No PCT/US2021/062168 Applicant PARTNER THERAPEUTICS, INC. Inventor MILLER, Greg
The present disclosure relates to a manufacturing process of sargramostim, which results in improved yield efficiency and output.
4.WO/2022/074628MULTIVALENT CORONAVIRUS BINDING MOLECULES AND USES THEREOF
WO 14.04.2022
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/IB2021/059262 Applicant THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO Inventor SIDHU, Sachdev
Described herein are synthetic multivalent binding molecules that bind to a coronavirus polypeptide, e.g., the spike protein of SARS-CoV-2 (the causative agent of COVID-19), compete with receptor binding to inhibit coronavirus infection. Also described are multivalent binding molecules that bind to the SARS-CoV-2 receptor binding domain (RBD) and exhibit neutralization potencies at sub-nanomolar concentrations against SARS-CoV-2/USA/WA1 in Vero E6 cells.
5.WO/2021/211414BISPECIFIC ANTIBODY COMPOSITIONS AND METHODS FOR TREATING COVID-19
WO 21.10.2021
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No PCT/US2021/026811 Applicant MADDON ADVISORS LLC Inventor MADDON, Paul J.
This invention provides a bispecific antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically binds to the extracellular portion of human TMPRSS2 (hTMPRSS2); (iii) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide; and (iv) specifically inhibits the entry into hACE2+/hTMPRSS2+ human cells of a pseudovirus bearing SARS-CoV-2 S protein. This invention also provides related pharmaceutical compositions, recombinant nucleic acid molecules, vectors, AAV particles, therapeutic and prophylactic methods, and kits.
6.WO/2021/236651COMPOSITIONS AND METHODS OF A NUCLEASE CHAIN REACTION FOR NUCLEIC ACID DETECTION
WO 25.11.2021
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/US2021/032977 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor SAVAGE, David
Described herein are nucleic acid detection compositions and systems comprising an internal nuclease chain reaction (NCR) for signal amplification and methods of using these NCR-containing compositions and systems.
7.WO/2022/081971NOTCH4 ANTIBODIES AND USES THEREOF
WO 21.04.2022
Int.Class C12P 21/08
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21Preparation of peptides or proteins
08Monoclonal antibodies
Appl.No PCT/US2021/055181 Applicant THE CHILDREN'S MEDICAL CENTER CORPORATION Inventor CHATILA, Talal
Provided herein are anti-Notch4 antibodies or antigen binding fragments thereof and their use in the treatment of a disease or disorder associated with increased levels of Notch4.
8.WO/2022/074621COVID-19-BINDING IMMUNOGLOBULINS AND METHODS FOR THEIR USE
WO 14.04.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/IB2021/059246 Applicant THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO Inventor SIDHU, Sachdev
Described herein are synthetic monoclonal antibodies, built on a human IgG framework, e.g., Trastuzumab, that bind to the spike protein of SARS-CoV-2 (the causative agent of COVID-19), compete for ACE2 binding, and potently inhibit SARS-CoV-2 infection and proliferation. The antibodies that exhibit neutralization potencies at sub-nanomolar concentrations against SARS-CoV-2/USA/WA1 in Vero E6 cells are bound to the receptor binding domain (RBD).
9.WO/2021/231751FUCOSYLATED OLIGOSACCHARIDES FOR PREVENTION OF CORONAVIRUS INFECTION
WO 18.11.2021
Int.Class C07H 5/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
5Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
04to nitrogen
06Aminosugars
Appl.No PCT/US2021/032283 Applicant GLYCOSYN LLC Inventor MORROW, Ardythe, L.
The invention provides compositions and methods for utilizing oligosaccharides, such as isolated human milk oligosaccharides, to attenuate a respiratory pathogen infection and/or to promote recovery from a respiratory pathogen infection in the respiratory system and/or the GI tract of a subject.
10.WO/2021/207962ANTIBODIES TO SARS-CORONAVIRUS (COVID-19) S1 SPIKE PROTEIN
WO 21.10.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2020/084857 Applicant ACTIVE MOTIF SHANGHAI LIMITED Inventor LU, Yanan
Provided are recombinant monoclonal antibodies that bind to the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2 or COVID-19) spike protein and using methods thereof. The antibodies can inhibit or neutralize SARS-CoV-2 activity, thus can be used for treating or preventing or diagnosing COVID-19 infection in humans.